VERIGRAFT Receives Regulatory Green Light: Patient Recruitment Completed in Groundbreaking Clinical Trial for Chronic Venous Insufficiency
Gothenburg, Sweden – May 27, 2025. VERIGRAFT AB is pleased to announce a major milestone in the development of its Personalized Tissue Engineered Vein (P-TEV) for the treatment of Chronic Venous Insufficiency (CVI). The Spanish Medicines Agency (AEMPS) has now formally approved an amendment confirming the completion of patient recruitment for the company’s ongoing Phase I/II clinical trial (TECVI-1), recognizing the strong safety profile of the P-TEV technology.
Severe CVI affects over four million people in the U.S. and Europe alone, leading to pain, immobility, and reduced quality of life. VERIGRAFT’s unique approach using natural personalized vascular grafts may offer the first true long-term curative option for these patients. The amendment – approved on May 14, 2025 – reflects the positive safety data accumulated in the trial to date. With this regulatory green light, VERIGRAFT can now officially conclude the recruitment phase and prepare for next steps toward pivotal efficacy trials in Europe and the United States. The milestone signals growing confidence from health authorities in VERIGRAFT’s ATMP platform and its clinical strategy, setting the stage for regulatory interactions and investor engagement in the upcoming studies.
“This is a critical moment for VERIGRAFT and for the millions of patients suffering from CVI without effective long-term treatment options,” says Dr. Petter Björquist, CEO of VERIGRAFT. “Our P-TEV product continues to demonstrate excellent safety and strong clinical potential. We are now accelerating toward late-stage development, with growing confidence and momentum.”
Visit VERIGRAFTs website.
For more information, please contact.
VERIGRAFT – Pernilla Gill – email pernilla.gill@verigraft.com
Media – Richard Hayhurst – richard.hayhurst@59north.bio
